Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...

Spain is investigating Novo Nordisk over concerns it may be illegally advertising its weight loss drugs Ozempic and Wegovy ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

The Howard County Board of Education is suing Eli Lilly and Co., Novo Nordisk, CVS, UnitedHealth Group and several other drug ...

IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...